Rockwell Medical, Inc., a global healthcare company specializing in the development, manufacturing, and commercialization of hemodialysis products, has appointed Joe Dawson to its Board of Directors.
The company also announced that Andrea Heslin Smiley has resigned from the Board to pursue other professional opportunities.
Joe Dawson brings more than 25 years of leadership experience across the renal care and cardiovascular markets, offering deep industry insight as Rockwell Medical continues to expand its market presence and pursue strategic growth initiatives. Throughout his career, Dawson has successfully negotiated and secured major customer contracts, led acquisitions into new product segments, and driven both top-line growth and operational profitability. His strong command of FDA-regulated environments, global supply chains, and medical device commercialization pathways positions him as a valuable strategic advisor to the Board.
Most recently, Dawson served as President of the North America Division at Nipro Medical Corporation, a wholly owned subsidiary of Nipro Corporation and one of the world’s largest medical device manufacturers. In this role, he held full P&L responsibility for U.S. operations, provided strategic and operational leadership, and maintained direct accountability for regulatory compliance across highly regulated therapeutic areas including dialysis, vascular access, and infusion technologies.
Prior to Nipro, Dawson held senior sales and management roles at Cordis Corporation, then a Johnson & Johnson subsidiary and a leading innovator in interventional vascular technologies. His earlier career began at W. L. Gore & Associates, a global materials science company known for advanced medical and industrial products.
Dawson holds a Bachelor of Science degree in Neurobiology from St. John’s University. His appointment strengthens Rockwell Medical’s Board as the company focuses on optimizing manufacturing networks, expanding product adoption, and advancing long-term business development strategies in the global dialysis market.
